(Reuters) – British drugmaker GSK said on Tuesday it would pay up to $3.3 billion to acquire privately held biopharmaceutical firm Affinivax, as it seeks to bolster its vaccine pipeline.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shailesh Kuber)
